| Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells J Walsby-Tickle, J Gannon, I Hvinden, C Bardella, MI Abboud, A Nazeer, ... Communications biology 3 (1), 247, 2020 | 71 | 2020 |
| Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations IC Hvinden, T Cadoux-Hudson, CJ Schofield, JSO McCullagh Cell Reports Medicine 2 (12), 2021 | 44 | 2021 |
| Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors R Reinbold, IC Hvinden, P Rabe, RA Herold, A Finch, J Wood, M Morgan, ... Nature Communications 13 (1), 4785, 2022 | 23 | 2022 |
| Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1 S Liu, MI Abboud, T John, V Mikhailov, I Hvinden, J Walsby-Tickle, X Liu, ... Communications Biology 4 (1), 1243, 2021 | 21 | 2021 |
| Nuclear magnetic resonance spectroscopy to identify metabolite biomarkers of nonresponsiveness to targeted therapy in glioblastoma tumor stem cells IC Hvinden, HE Berg, D Sachse, E Skaga, FS Skottvoll, E Lundanes, ... Journal of proteome research 18 (5), 2012-2020, 2019 | 7 | 2019 |
| Exploring metabolic vulnerability and therapeutic potential in cancers with isocitrate dehydrogenase mutations IC Hvinden University of Oxford, 2022 | | 2022 |
| Nuclear magnetic resonance spectroscopy based metabolomics discovers biomarkers of glioblastoma drug response IC Hvinden | | 2018 |
